. Author manuscript; available in PMC: 2010 Aug 1.

Published in final edited form as: Clin Lymphoma Myeloma. 2009 Aug;9(4):307–310. doi: 10.3816/CLM.2009.n.060

Table 1. Overview of included studies.

							Subjects older than 40 years

Series, year of publication	Treatment Period	Treatment Regimen	Total N	Median Age	Age Range	Overall Survival	N	% of Total N	Overall Survival
Fenaux, 1989¹⁰	5/81 - 12/87	ALL-like regimen; 4 pts with SCT	18	26	16-66	30.0%	4	22%	25.0%
Pees, 1992¹¹	1982-1990	Short duration/dose intensive; pediatric NHL based	14	39	16-65	71.0%	5	36%	80.0%
Soussain, 1995¹²	9/84 - 8/91	ALL-like regimen	65	26	17-65	75.0%	12	18%	67.0%
Hoelzer, 1996¹³ B-NHL83	7/83 - 6/89	Short duration/dose intensive; pediatric NHL based	24	33	15-58	49.0%	9	38%	33.0%
Hoelzer, 1996¹³ B-NHL86	7/89 - 1/93	Short duration/dose intensive; pediatric NHL based	35	36	18-65	51.0%	15	43%	40.0%
Magrath, 1996⁵	10/77 - 12/93	CODOX-M/IVAC	54	N/A	N/A	89.0%	3	6%	33.0%
Thomas, 1999¹⁴	9/92 - 6/97	Hyper CVAD	48	58	17-79	39.0%	28	58%	35.0%
Mead, 2002¹⁵	10/95 - 5/99	CODOX-M/IVAC	52	27	15-52	70.0%	23	44%	65.2%
Smeland, 2004¹⁶	1982-2001	Short duration/dose intensive; ASCT	36	N/A	15-69	regimen 2: 71%; regimen 3: 65%	16	44%	62.0%
Rizzieri, 2004¹⁷	5/92 - 2/00	Short duration/dose intensive	92	47	17-78	cohort 1: 54%; cohort 2: 50%	58	63%	39.0%
Lacasce, 2004¹⁸		Modified CODOX-M-IVAC regimen	14	47	18-65	71.0%	9	64%	67.0%
van Imhoff, 2005¹⁹	12/94 - 2/03	Short duration/dose intensive; ASCT	27	36	15-64	81.0%	11	41%	82.0%
Thomas, 2006²⁰	2/00 - 1/05	Hyper CVAD + Rituximab	31	46	17-77	89.0%	19	61%	89.0%
Kujawski, 2007²¹	1/95 - 8/02	Short duration/dose intensive	10	51	35-71	72.0%	7	70%	71.0%